inter-batch variability? [Regulatives / Guidelines]

posted by d_labes  – Berlin, Germany, 2010-08-04 15:58 (5406 d 00:45 ago) – Posting: # 5715
Views: 17,616

Dear Dan!

❝ Study 1: 111/116

❝ Study 2: 84/95

❝ Study 3: 111/114

❝ Study 4: 98/97

❝ The assessor concludes that these different point estimators hint at inter batch variability of the test product [color:red](why not the reference?)/color:red] and therefore a marketing authorisation can not be granted.

(emphasis by me)

:not really:
I never heard about a regulatory criterion requesting that the point estimators between BE studies must not varying. And that you must express articulately against the regulatory body.
I would wonder if there is no variability!

As you have told: the pivotal studies have shown bioequivalence. IMHO that was it. All other concerns are negligible (if not safety is concerned).

More over the assessors judgment is logical flawed:
Considering Study 1/Study 3 with the same reference 1 (batch?), neglecting the fact that study 1 is pilot and therefore not suitable for a reliable point estimator, there is no substantial difference in the point estimators although test 1 and test 2 (batches?) are used.
Since the other 2 studies use different test/reference (batches?) one cannot use them to judge. If judgment of inter-batch variability is ever possible from BE studies which I highly question.

But to cite myself: "Regulators ways are inscrutable!"

Eventually you can argue using not the point estimators but the mean/geometric mean values of the PK metrics themselves. Hopefully they show greater variability between the reference batches.
But IMHO this is clearly nonsense.

Regards,

Detlew

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,681 registered users;
49 visitors (0 registered, 49 guests [including 26 identified bots]).
Forum time: 16:43 CEST (Europe/Vienna)

Pharmacokinetics may be simply defined as
what the body does to the drug,
as opposed to pharmacodynamics, which may be defined as
what the drug does to the body.    Leslie Z. Benet

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5